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Abstract. Pectus excavatum is the most common congenital chest wall abnormality expressed in 34 
children, yet its inheritance is poorly understood. Here we present the first comprehensive 35 
assessment of the inheritance of this disorder. After evaluating 48 pedigrees and 56 clinical traits 36 
of probands and family members, we find strong evidence of autosomal recessive, genetic 37 
control for this disorder. Additionally there is likely more than one disease-associated allele as 38 
well as a relatively large number of disease allele carriers in the human population. Some clinical 39 
traits appear important and may serve as reliable indicators for predicting the likelihood of PE in 40 
children before severe symptoms present. Quantifying sex-ratio bias in probands demonstrates a 41 
highly significant male bias associated with PE. When combined with pedigree data, sex-bias is 42 
indicative of sex-linked, sex-limited, and/or epigenetic control such as X-inactivation, reiterating 43 
a point made with pedigrees alone, which is that more than one mutation is likely responsible for 44 
this disorder. 45 
 46 




1. Introduction 48 
 49 
Pectus excavatum (PE) is the most common congenital chest wall malformation, occurring in 50 
~1/400 infants and children, primarily male (1-3). The PE phenotype is expressed as an anterior 51 
chest cavity depression that results from rotation, displacement, and depression of the sternum. 52 
PE has previously been qualitatively described to some degree, yet despite a very high rate of 53 
occurrence, its heritability has been only cursorily evaluated (2). PE probands present with 54 
various clinical features also found with Marfan syndrome, another connective tissue disorder. 55 
Additionally, over one-quarter (28%) of Marfan syndrome probands express PE (4-5).  56 
Multiple, independent mutations in the FBN1 (15q21) gene are associated with a range of 57 
clinical manifestations of Marfan syndrome (5-6). While no single gene, or large-scale genomic 58 
studies have been conducted on the inheritance of PE, several genes, including FBN2 (5q23-31), 59 
COL2A1 (12q13), ACAN (15q26.1), TGFβ (19q13) and receptors (TGFβr1 (9q22), TGFβr2 60 
(3q22), and TGFβr3 (1p33)) are associated with connective tissue disorders and thus could be 61 
considered candidate loci for PE. Very recent work evaluating one family via genome-wide 62 
linkage analysis suggested partial genetic control of PE on chromosome 18, however no 63 
causative genes were identified (7).  64 
Here we assess 48 pedigrees and a broad array of clinical traits (n=56) in more than 2,000 65 
individuals over 100 of whom have PE. Visual inspection of probands provides evidence for 66 
multiple, conspicuous clinical features (e.g. tallness, thinness, light-eyes) that commonly 67 
manifest with PE. We have quantified data related to several clinical traits and added this to 68 
conventional pedigrees that we have constructed. We find that this trait-related information 69 
contributes to predicting the likelihood that an individual inherits PE. We present results from 70 
our analysis of a comprehensive data set to provide evidence that PE is an autosomal, recessive 71 
  
 4 
trait or results from polygenic inheritance. We suggest chromosomal regions relevant for future 72 
genome wide association studies for PE-alleles. We show evidence for the Carter effect (8), a 73 
polygenic inheritance pattern with a susceptibility threshold that differs for the sexes and that 74 
results in a predictable sex-related transmission pattern (9, 10). We demonstrate evidence of 75 
strong male bias in probands. Finally, we estimate the frequency of PE alleles and of carriers in 76 
the human population. Results from our study may prove useful for determining the likelihood of 77 
development of this disorder in unborn children and for locating genes controlling PE. 78 
2. Materials and methods 79 
Pedigree construction, inheritance, and sex-ratio 80 
We have constructed pedigrees (Figure 1) based upon detailed information obtained during 81 
medical examination of probands and from self-reported data of immediate family members of 82 
individuals with PE severe enough to warrant surgical correction. Eastern Virginia Medical 83 
School IRB approved questionnaires were used to obtain these data, which address filial history 84 
of PE and a broad array of clinical features (discussed below). The population assessed is of 85 
national origin, though is comprised primarily of Caucasian males from the mid-Atlantic. They 86 
are a subset of the national registry of individuals at the Children’s Hospital of The King’s 87 
Daughters seeking surgical intervention. Forty-eight family pedigrees are constructed and each is 88 
comprised of at least four, and sometimes five, generations (though little information was 89 
typically known for the eldest generation).  90 
The likelihood that spontaneous mutation, or a particular inheritance pattern (here 91 
considered: X-linkage, Y-linkage, autosomal dominant, autosomal recessive or semi-dominant 92 
control, sex-linkage coupled with an autosomal modifier, or polygenic inheritance), best explains 93 
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each pedigree is evaluated. This conventional analysis excludes impossible scenarios but does 94 
not yield a single, inheritance pattern for each family. 95 
Therefore we supplemented the pedigrees with data regarding genes that control PE-96 
associated clinical traits onto our pedigrees and re-evaluated for most probable mode of 97 
inheritance. Persons with autosomal traits that might be linked to PE genes demonstrate potential 98 
heritability information not available in the first analysis (e.g. what previously appeared, perhaps 99 
erroneously, to be a spontaneous mutation may now present with parent carrier phenotypes) and 100 
a polygenic mode of inheritance is plausible. Hence, the Carter effect is examined by assessing 101 
the relative rate of transmission of PE from females with PE (compared to males) to progeny 102 
with the expectation that women transmit to their progeny at a higher rate if a polygenic 103 
threshold model fits these data. Six additional families are added for this analysis only, to 104 
increase the sample size of the smallest cells in the contingency tables. The two by two 105 
contingency table is presented for all children (with and without PE) that have one parent that 106 
expresses PE (Table 2). Data are then presented for this same group of children, partitioned by 107 
sex. A binary logistic regression was performed to assess the association between mothers or 108 
fathers that had PE and their progeny that did (versus did not) express the disorder. An odds ratio 109 
is presented with 95% confidence intervals and the p value for the associated Chi-square test.  110 
Another table (Table 3) is presented to evaluate the association between the number of 111 
siblings expressing PE (versus not) when the sex of the affected individual is male versus female. 112 
The same analyses are presented. Analyses were conducted using SPSS 12.0 (IBM, NY, USA). 113 
 Finally, we evaluated sex ratio bias in individuals with PE. Pearson chi-square analysis was 114 
conducted on the male: female ratio observed in the pedigrees (11). Several cases of pectus 115 
carinatum (PC, a similar disorder to PE except here the chest wall is everted) were reported in 116 
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families with PE. Since the inheritance of PC is also not understood, we analyzed the sex ratio 117 
for PC with an exact binomial test for goodness of fit for deviation from 1:1 (12).  Miscarriage 118 
data were also evaluated to determine whether a lethal allele might drive the sex ratio bias 119 
observed in PE (e.g. XPE causes PE in males and XPEXPE is lethal in females). 120 
Quantification of clinical traits 121 
Fifty-eight clinical traits were assessed for 56 families to identify the traits most frequently 122 
associated with PE. Traits generally fell into broad categories including cardiac function, 123 
musculo-skeletal system function, and behavior. Some specific traits included mitral valve 124 
prolapse, height, finger length, skin tone, myopia, ADHD and depression. Table 1 ranks the 10 125 
most common traits for individuals with PE and compares this to the 10 most common traits for 126 
family members without PE. 127 
Using NCBI human genome data (13) to identify chromosomal locations of genes controlling 128 
the common traits assayed, we created a trait-related genomic map (Figure 2), allowing us to 129 
collect data on specific chromosomes that might be more likely to carry PE-related genes if 130 
linkage exists between these clinical trait genes and PE genes.  131 
‘Tall’ and ‘thin’ are clinical traits commonly associated with PE but only qualitative data was 132 
included in our database regarding these. Therefore, we obtained independent quantitative data 133 
on these traits in individuals with PE from the thread found at the website dedicated to PE where 134 
individuals communicate regarding their condition (14). This thread included 179 self-reported 135 
responses to the Oct 6, 2004 query ‘How tall/thin are you PE people?’  We performed chi-square 136 
tests to compare average height and weight between individuals with PE and the U.S. adult 137 
population.  138 
Estimating the frequency of heterozygotes 139 
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If PE arises from autosomal recessive mutations like many other human diseases then the 140 
expected frequency of heterozygous carriers can be calculated, assuming Hardy-Weinberg 141 
equilibrium. We perform this calculation using the phenotypic expression range found in the 142 
literature (1/400-1/1,000 individuals) for PE. We address single- versus multiple-gene 143 
involvement in PE and the effect on this calculation. 144 
 3. Results 145 
Pedigree construction, PE-inheritance, and sex-ratio 146 
A total of 2,147 individuals were evaluated from 56 families, wherein 116 individuals 147 
present with PE. Cumulatively, inheritance patterns across families reveal the likelihood that 148 
more than one PE-associated allele, and possibly an epigenetic effect are important in the 149 
heritability of this disorder.  150 
As predicted, the conventional method of pedigree analysis is not an especially powerful 151 
technique with these data because of the small amount of information available on the pedigrees 152 
(e.g. one or a few individuals with PE). Thus, multiple inheritance patterns are possible 153 
explanations for disease for most families. When we test whether spontaneous mutation fits as an 154 
explanation for PE in each family, we find that it cannot be excluded as a possibility for 17 155 
families (and it is a poor fit for 26 families). For five additional cases where PC is also present in 156 
the family, spontaneous mutation would explain PE only if PC is genetically unrelated.   157 
When we test each pedigree for autosomal control, we find that this could explain the 158 
inheritance of PE in all families. However a standard null model for autosomal disorders is that 159 
about one-half of cases will be male and one-half female. Our data prove inconsistent with the 160 
50:50 sex ratio given the large male-bias observed with PE. Autosomal recessive transmission 161 
here also requires multiple marriages to heterozygous individuals in many families, or an 162 
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epigenetic effect, or sex-limited expression. This fact spurred our Hardy-Weinberg calculation so 163 
that we could evaluate the expected PE carrier rate.  164 
 Alternatively, sex-linked expression combined with an autosomal modifier describes the 165 
pedigrees fairly well: X-linkage (or sex limited expression) plus a dominant or recessive 166 
autosomal modifier can explain most cases of PE. The limitation of this analysis is that X-167 
linkage plus a modifier is not always a conservative explanation. X-linkage alone is supported 168 
for 19 pedigrees and refuted for 19. For five additional cases, X-linkage is very unlikely. For the 169 
remaining five cases X-linkage would be contingent upon the relationship between the 170 
inheritance of PC and PE.  171 
 Finally, when we assess Y-linkage across pedigrees, Y linkage (or sex limited expression) 172 
plus a dominant or recessive modifier could not be excluded as explaining the inheritance of PE. 173 
However, in no case would Y-linkage alone be supported.  174 
A more powerful analysis than the above is revealed when incorporating the relevant clinical 175 
traits (Table 1) on the pedigrees atop the data regarding PE, since heterozygous individuals will 176 
express all linked dominant or semi-dominant (or homozygous recessive) clinical traits, which 177 
proves useful for identification of putative PE allele carriers. With this analysis, only two cases 178 
of PE are predicted to result from spontaneous mutation, which is more consistent with the very 179 
low de novo mutation rate for humans (~10-5-10-6) (15) than the result from the first analysis. 180 
The phenotypic expression of PE across generations, though skipping generations in many 181 
pedigrees, reinforces the concept that carriers are likely to be important in the inheritance of this 182 
disorder. In fact, the inheritance pattern on nearly all pedigrees suggests that linkage with 183 
specific regions of chromosome 5 (or, plus 15 and/or 17) is worthy of future genome wide 184 
analysis. Here, 19 pedigrees are best fit by a simple autosomal inheritance pattern (13 recessive 185 
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and six either dominant or recessive). In ~84% of them (16 out of 19 pedigrees), chromosome 5 186 
associated-traits appear prominently in family members for whom they might be expected if 187 
these traits are linked to PE genes. In three of the autosomal recessive cases, chromosome 15 188 
appears similarly.  189 
Twenty pedigrees appear best explained by a polygenic effect, where again clinical traits 190 
from one or two chromosomes (namely 5 or 15, and/or 17) are inherited in a manner that is 191 
consistent with transmission of PE through the family and thus linkage to PE genes warrants 192 
future genome wide studies focusing on these chromosomes: chromosomes 5 and 17 appear 193 
relevant for five pedigrees, 5 and 15 for six pedigrees, and 5 or 15 and 17 for six more pedigrees. 194 
A role for chromosomes 15 and 17 appears relevant for three pedigrees, for chromosome 5 and 1 195 
or X important for two pedigrees, and for chromosome 15 and either 7 or X for two more 196 
pedigrees. A role for chromosome 7 appears for three pedigrees and one of these looks to have a 197 
spontaneous mutation. A final pedigree also appears to present with a spontaneous mutation and 198 
no chromosomal traits appear important.  199 
Thus, a role for chromosome 5 appears in over half (62.5%, or 30/48) and perhaps as many 200 
as 75% (36/48) of the pedigrees. Chromosome 15 appears important for between one-third (29%, 201 
14/48) and ~42% (20/48) of the pedigrees. Chromosome 17 appears important in nearly one-fifth 202 
(18.75%, 9/48) and up to 31% (15/48) of the pedigrees.   203 
Results from the test for a polygenic mode of inheritance with a threshold that differs by sex 204 
are shown in Table 2. The rate of transmission from affected mothers (with PE) to children is 205 
64% (16/24) and affected fathers to children is 33% (20/59).  The Chi-square P value is 0.008 206 
and the risk of transmission from mothers over fathers is 3.900, though the confidence interval 207 
surrounding the odds ratio is 1.427-10.659. Partitioning this data by the child’s sex shows that 208 
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mothers transmit to their female children in 70% of the cases (7/10) whereas fathers transmit to 209 
female children in 17.39% of the cases (4/23). Mothers transmit to sons in 64.28% (9/14) of the 210 
cases whereas fathers transmit to sons in 44.46% of the cases (16/36). Odds ratios in both cases 211 
suggest that the risk of transmission is higher when the affected parent is female (Table 2).  212 
Table 3 demonstrates the rate of PE in affected mother’s siblings versus affected father’s 213 
siblings, which addresses the relative genetic load in affected females versus males. Mothers 214 
have 33.33% affected siblings (9/27) whereas fathers have 7.2% (7/96). The odds ratio (6.357) is 215 
skewed toward a higher likelihood of the disorder in siblings of affected females.   216 
The strong deviation from the 1:1 sex ratio suggests that sex-chromosomes, sex-limited 217 
expression, sex-related lethal alleles, or sex-related epigenetic control must be involved in some 218 
cases of PE. No useful traits were available to assess on the Y chromosome and X-chromosome 219 
traits were considered important in at least three pedigrees. 220 
In cases where PC is also found in a family, the analysis is challenging, since the literature 221 
does not indicate a specific, known genetic association between these two disorders. Despite this, 222 
25% (12/48) of families with PE also demonstrate PC in our pedigrees (two families have 223 
multiple cases of PC).   224 
Evaluating sex ratio across all PE cases, we observe a strong male bias of nearly 4:1, where 225 
the exact ratio is 92:24, which reduces to 3.833:1 and deviates strongly from 1:1 (X2 0.05, [1]= 226 
39.863, p<0.0001), or the conventional expectation for autosomal control whether inheritance is 227 
controlled by one gene or is polygenic. A more extreme, 8-fold male bias is observed in cases 228 
where the proband is an only child. Here, the exact sex ratio is 17:2, which reduces to 8.5:1 and 229 
deviates from 1:1 (X2 0.05, [1]= 11.842, p<0.00006), indicating that 89% of these probands are 230 
male. Thirty families present with an only-child that has PE. For these, a 9-fold male bias occurs 231 
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and the exact sex ratio is 27 males: 3 females, which reduces to 9:1 and deviates from 1:1, X2 0.05, 232 
[1]= 19.2, p<0.0001). In contrast, in families with sibships where at least one sibling has PE, there 233 
is a 3-fold male bias and the exact sex ratio is 50:14, which reduces to 3.57:1 and deviates from 234 
1:1 (X2 0.05, [1]= 20.250, p<0.0001). Similarly, the respondents to the online database questions 235 
who indicate their sex (131 individuals) also demonstrate a 3-fold male bias, where the exact sex 236 
ratio is 101:30, which deviates from 1:1 (X2 0.05, [1]= 38.481, p<0.0001). 237 
 Since extreme male bias is suggestive of lethal XPEXPE, the sex ratio for the number of living 238 
offspring in a sibship where miscarriage was reported for the mother was evaluated and 239 
determined to be ~1:1 (12:13). This does not suggest a disproportionate number of reported 240 
miscarriages that were female. Only two sibships were comprised of both PE and miscarriage, 241 
and in each there was one live male child with PE. One of these mothers reported one 242 
miscarriage and the other mother reported five. Under 1:1 sex ratio, this would suggest that four 243 
females and two males were miscarried.  244 
A second possibility explaining male bias involves the masking of a recessive XPE by a wild-245 
type X in females. This would result in male biased disease expression (XPE is not masked by Y), 246 
as would biased X-inactivation in females, but no expectation of a sex ratio bias in living 247 
children was found in sibships with miscarriage. For the recessive X there is a predicted 248 
inheritance pattern (heterozygous-mother to expressing son), which is sometimes, but not 249 
always, evidenced in our pedigrees. Our pedigrees also include 14 cases of PC (79% in males; 11 250 
male: 3 female), which demonstrate a reduced sex ratio of 3.66:1. This is similar to the bias 251 
observed for PE.  252 
Quantification of clinical traits 253 
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The average number of clinical traits that individuals with PE have is 5.73 ± 3.48. For family 254 
members without the disorder the average is 0.14 ± 0.085. After excluding individuals with zero 255 
traits, the non-PE family members’ mean is still lower, at 2.80 ± 0.87, than for those with PE. 256 
The 10 most common clinical traits identified in individuals with PE and their families in this 257 
study are reported in Table 1. Ranked from 1-10 for individuals with PE these are: thinness (47% 258 
of individuals with PE), braces (41%), myopia (40%), tallness (33%), light eyes (29%), long 259 
fingers (25%), creativity (25%), crowded teeth (25%), fair skin (22%), and asthma (20%). The 260 
ranking of these traits in family members without the disorder changes and the frequency of the 261 
top 10 PE-related traits is always substantially less for family members than for individuals with 262 
PE.  263 
The chromosomal locations for genes that are known to be associated with the traits are 264 
pictured in Figure 2. Some of these are: light eyes (5p13.2, 9p23, 15q11.2, 15q13.1), fair skin 265 
(5p13.2, 15q21.1 and 16q24.3), asthma (1q32.1, 5q31-33, 7p14.3, 17q12-21.1 and 20p13) and 266 
myopia (1p36, 2q37.1, 3q26, 4q22-q27, 4q12, 5p15.33-p15.2, 7q36, 7p15, 8p23, 11p13, 12q21-267 
q23, 17q21-q22, Xq28, Xq23-q25). 268 
Figure 3 lists the 10 most common PE-related traits and identifies which members of the 269 
immediate family (mother, father, proband) have each trait. Traits shared between the proband 270 
and both parents arise 21 times (yellow cells), between the proband and the mother, 29 times 271 
(pink cells), and between the proband and the father, 44 times (light blue cells). This figure also 272 
displays the traits that are found only in the proband, which arise 89 times (gray cells), only in 273 
the mother, which arise 33 times (dark red cells), only in the father, which arise 39 times (black 274 
cells), and between the mother and father, which arise 9 times (green cells). The proband has 275 
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over twice as many traits as either of his parents (2.69 times more than his mother and 2.28 times 276 
more than his father). 277 
Regarding height, boys and girls with PE are taller and thinner than the average male and 278 
female in the U.S. The average height of adult men (20+ yrs) in the U.S. is 5’9.4” and the 279 
average weight is 194.7 lb. (16). Analysis of the PE web site height/weight data indicates that 280 
males with this disorder are taller than this, despite being younger: 47 of the 54 male individuals 281 
whose data we could analyze (complete information supplied) exceeded 5’ 9” and seven were 282 
shorter. An appropriate null expectation for height (a normally distributed trait) is that about half 283 
of the population (or here the PE subpopulation) will be taller than average (and for PE this 284 
would be 27 males), and half will be shorter. Our data deviate substantially from this expectation 285 
since 47 of 54 men with PE are taller than average than average (Χ2[0.05],1 = 29.629, p <0.0001). 286 
Further, of the 7 males shorter than 5’9”, three are less than18 yrs and four are less than 20 yrs 287 
old. In addition, of the 47 males above 5’9”, nine are not yet 18 yrs old and are expected to 288 
continue to grow. The average age for males evaluated from the web site data was 22.63 yrs. 289 
Individuals < 20 yrs were included in the comparison because we had complete data on them 290 
(making inclusion possible, which seemed reasonable since this is a conservative action given 291 
that they can only grow taller with increasing age). Removing the heights of the boys under 20 292 
yrs from the analysis, the result remains highly significant. Similarly, of the 34 men ≥ 20 yrs for 293 
which we could calculate weight, their average weight was 174.14 lbs. This is ~20 lbs less than 294 
the average reported for U.S. men (16). 295 
The average height of adult women in the United States is 5’3.8” and average weight 164.4 296 
lbs. (16). Females with this disorder are also taller and thinner than the average woman (Χ2[0.05],1 297 
= 9.9 and the 0.001< p <0.01). Of the females’ query responses we were able to analyze, five 298 
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females were < 5’4” and 20 were taller. The average age for the women evaluated from the web 299 
site data was 26.1 yrs. Of the five women < 5’4”, one was under 18 yrs and potentially still 300 
growing. Of the 20 over 5’4”, five were ≤18yrs and 2 were ≤ 20yrs. Similarly, of the 14 women 301 
≥ 20 yrs for which we could calculate weight, the average weight was 119.07 lbs which is ~45 302 
lbs less than the average reported for U.S. women (16). 303 
Estimating the frequency of heterozygotes 304 
Our pedigree assessment indicates that autosomes are likely involved in this disorder but we 305 
find that a relatively large number of marriages between heterozygous individuals must occur if 306 
this is true. If PE is a result of a homozygous recessive genotype, then individuals that are 307 
heterozygous for alleles causing PE are predicted to be relatively common. If the disease 308 
phenotype is represented by the autosomal recessive genotype, ‘rr’, then the frequency ‘rr’ in the 309 
population is 0.0025 (from the reported 1 in 400 have the disorder). In Hardy Weinberg, p2= 310 
0.0025, so p = 0.05, q = 0.95 and the frequency of heterozygotes (2pq) equals 0.095, implying 311 
that 9.5 in 100 individuals will carry ‘r’.  This number could increase if PE is additive and 312 
polygenic. If two independent mutations cause PE, then 19/100 carriers would be expected and if 313 
three independent mutations cause PE then 28.5/100 carriers would be expected. 314 
Similarly, if the frequency of ‘rr’ = 0.001 (from the reported 1/1,000) then q=0.969 and 2pq 315 
= 0.060. Thus, between 6/100 and 9.5/100 individuals would be carriers of an autosomal 316 
recessive allele if one recessive mutation causes PE, and as many as 29 in 100 individuals if say, 317 
three independent mutations cause PE. Thus, a large number of heterozygotes would exist in the 318 
human population.  319 
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Many cases of PE fit the autosomal, recessive inheritance pattern well and those that do not 320 
generally appear to be sex-linked and under autsomal modifier control. The above calculation 321 
would also apply for an autosomal modifier.  322 
4. Discussion 323 
Little is known regarding the genetics and inheritance pattern of pectus excavatum. This 324 
work advances our knowledge on many fronts. Spontaneous mutations causing human disease 325 
occur on the order of ~10-5 to 10-6, yet as many as 1 in 400 people express PE, indicating that the 326 
majority of cases must not result simply from de novo mutations. Knowledge regarding clinical 327 
traits commonly associated with PE (like thinness, myopia, crooked teeth and tallness) may be 328 
useful during genetic counseling for predicting the probability of transmission of PE alleles. The 329 
Carter effect addresses the likelihood of the lesser-affected sex carrying a higher genetic load and 330 
expressing a disorder less frequently (than the opposite sex) while being more likely to transmit 331 
to progeny and to also have siblings that are affected. Data from our assessment of the Carter 332 
effect may also be useful in genetic counseling since it points to a higher probability of mother’s 333 
with PE (versus father’s with PE) transmitting the disorder to offspring, as well as these 334 
women’s siblings having a higher likelihood of being affected with PE. However, caution must 335 
be exercised in drawing full conclusions here since the confidence intervals surrounding these 336 
odds ratios tend to be large with our present sample sizes.  337 
Since the average height and weight of individuals with PE deviates from the norm and 338 
demonstrates the unconventional pattern of a negative association (e.g. tall and thin), the 339 
predictive power of this trait combination is enhanced. 340 
The relatively high frequency of PE in the human population makes it plausible that a 341 
substantial number of heterozygous individuals are involved transmission. The presence of 342 
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clinical traits in a disproportionate number of probands’ parents and siblings may reflect an 343 
abundance of heterozygous carriers, predicted here to be at least 38-60 fold more common than 344 
diseased individuals. This indicates that marriages to heterozygous carriers could occur 345 
frequently. 346 
The sex-ratio associated with PE deviates substantially from the conventional expectation for 347 
pure autosomal control. This is indicative of sex-linked or sex-limited (epigenetic) expression. 348 
Male bias may result if more than one independent mutation causes PE and at least one of these 349 
is sex-linked, or if females must have a higher number of specific alleles to express PE because 350 
of a sex-related susceptibility difference. Or it may result if gene interactions or sex-related gene 351 
silencing occur. Thus, the role for genes like SOX5 (12p12.1) and SOX9 (17q24.3-q25.1) that 352 
interact during chondrogenesis, activate transcription of COL2A1 (12q13.11), are associated with 353 
sex determination and related to disease (17), should be further explored. 354 
Alternatively the biased sex-ratio (which demonstrates even greater bias for sibships with an 355 
only child with PE) could result from lethal XPEXPE. The sex ratio produced by the mothers that 356 
reported miscarriages did not suggest a female-bias in miscarried individuals. However, the 357 
sibships comprised of individuals with PE and miscarriages could, except our sample is too small 358 
to evaluate objectively so further study is warranted.  Another possibility involves the masking 359 
of a recessive XPE by a wild-type X, which would result in male biased PE expression (XPE is not 360 
masked by Y), as would biased X-inactivation in females. Here, there is no expectation of a sex 361 
ratio bias in living children found in sibships with miscarriage, but for the recessive X there is a 362 
predicted inheritance pattern (heterozygous-mother to PE-expressing son), which is sometimes, 363 
but not always, evidenced in our pedigrees. Noteworthy is that in sibships of more than one child 364 
and inclusive of a proband, sex ratio is less biased, potentially indicative of multifactorial 365 
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inheritance or more than one inheritance pattern and/or epigenetic effects for PE. Biased sex 366 
expression, such as we see, is expected when there is a sex-dependent threshold for a trait, as 367 
holds for the Carter effect.  368 
Other human diseases, such as Prader-Walli syndrome, demonstrate de novo deletions on 369 
chromosome 15 (at 15q11-13) exclusively of paternal origin, and in a few cases maternal 370 
heterodisomy (where two different copies of chromosome 15 are inherited maternally) (18) is 371 
indicative of epigenetic control. Unlike most human diseases, some (including neurofibromatosis 372 
and Duchenne muscular dystrophy) are associated with a high frequency of de novo germ-line 373 
mutations (19) which result from older sires (in many taxa, especially mammals) that express a 374 
higher germ-line mutation rate (spermatogenic cells from old mice have higher mutation rates 375 
than young- or middle-aged mice (19). While we cannot definitively state whether our probands 376 
have novel mutations, we are in the process of evaluating whether sire age plays a role in PE 377 
(85% of probands’ sire are over 30 years old), as it does in Marfan syndrome (17) (which affects 378 
~0.0001-0.0005 of the population) (21-23). 379 
There is definitive overlap in traits associated with PE and Marfan syndrome (9) including 380 
myopia, dental crowding, scoliosis, and long-fingers (23-25). PE and PC are also identified in 381 
about half of the individuals with Marfan syndrome, potentially suggestive of similar causation 382 
(24-27) and given the abundance of clinical traits involved, leading us to recommend that PE 383 
also be referred to as a syndrome.  384 
However, Marfan syndrome demonstrates a 1:1 sex ratio (24) indicative of pure autosomal 385 
control, unlike the Pectus disorders. The FBN1 gene (15q21.1) has been implicated as the 386 
predominant cause of Marfan syndrome (28-29) with additional mutations found in TGFßR2 387 
(e.g. 3p24.1) (30).  While chromosome 15 appears important in our analysis for PE, TGFßR1 and 388 
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TGFßR2 are typically associated with Marfan syndrome II, which is less similar to PE than 389 
Marfan syndrome.  390 
Our current knowledge suggests the potential for greater than one mutation to be associated 391 
with PE and the likelihood of sex-biased, polygenic control. Our data points to a clear need for 392 
genome-wide analysis of control of this disorder and follow through on establishing the 393 
importance of the links identified in this paper in a quantitative analysis. Regions of 394 
chromosomes 5, 15, and 17 are relevant for linkage mapping and candidate gene searches since 395 
relevant PE-associated clinical traits are controlled by genes on these chromosomes. Genes 396 
affecting cartilage are also found on these chromosomes and mutations in some of these genes 397 
control other syndromes demonstrating symptoms similar to PE. Aggrecan (ACAN, 15q26.1, a 398 
major proteoglycan of cartilage (31) accounts for 35% dry weight of cartilage (32) and two 399 
fibrillin genes (e.g. FBN1, 15q15-21.3 and FBN2, 5q23-31) affect connective tissue, causing 400 
Marfan and Marfan-like syndrome (33). While this work advances our knowledge regarding PE 401 
substantially, candidate gene searches for PE-related mutations are a necessary next step to 402 
identifying the causative agent of PE. Equally important are microarrays to look for differences 403 
in gene expression between individuals with PE, without PE, and those predicted to be 404 
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Figure 1. Pedigree with traits added for the mother, father and proband (additional family 650 
member traits not included here for clarity). Father and proband have pectus excavatum 651 
(darkened symbol). Proband is labeled with an arrow.    652 
 653 
Figure 2. Genomic map of chromosomal gene locations for traits evaluated in this study of 654 
pectus excavatum The genes for asthma include CHI3L1 (1q32.1) (34), IL12B (5q31.1-q33.1) 655 
(35), NPSR1 (7p14.3) (36), ORMDL3 (17q12-q21.1) (37), and ADAM33 (20p13) (38). The 656 
genes used for arthritis include PTPN22 (1p13.3-p13.1) (39), FCRL3 (1q21-q22) (40), AFF3 657 
(2q11.2-q12) (41), STAT4 (2q32.2-q32.3) (42), IL2 (4q26- q27) (43), HLA-DRB1 (6p21.3) (40), 658 
TRAF1 (9q33-q34) (42), and CCL5 (17q11.2-q12) (44). The genes used for ADHD include 659 
ADHD5 (2q21.1) (45), DRD5 (4p16.1) (46), SLC6A3 (5p15.3) (46), ADHD4 (5p13) 660 
(47), ADHD3 (6q12) (47), HTR1B (6q13) (46), DRD4 (11p15.5) (46), TPH2 (12q21.1) (46), 661 
ADHD6 (13q12.11) (45), ADHD1 (16p13) (47), ADHD2 (17p11) (47), and SNAP-25 (20p12-662 
p11.2) (46). The genes used for depression include HTR1A (5q11.2-q13) (48), TPH1 (11p15.3- 663 
p14) (49), BDNF (11p13) (50), TPH2 (12q21.1) (51), SLC6A4 (17q11.1-q12) (52), and MAOA 664 
(Xp11.3) (53). The genes used for fair skin include SLC45A2 (5p13.2) (54), SLC24A5 (15q21.1) 665 
(55), HERC2 (15q13) (56), and MC1R (16q24.3) (57). The genes used for hearing loss include 666 
KCNQ4 (1p34) (58), OTOF (2p23.1) (59), GJB2 (13q11-q12) (60), MYO1C (17p13) (61), and 667 
MYO1F (19p13.3-p13.2) (61). The genes used for light eyes include SLC45A2 (5p13.2) (56), 668 
SHEP11 (9p23) (62), OCA2 (15q11.2-12) (63), and HERC2 (15q13) (64). The genes used for 669 
light hair include SHEP11 (9p23) (62), OCA2 (15q11.2-12) (65), HERC2 (15q13) (65), MC1R 670 
(16q24.3) (57), and ASIP (20q11.2-q12) (66). The genes used for migraines include MGR 671 
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(1q31) (67), MA (4q24) (68), MGR8 (5q21) (69), MGR3 (6p21.1-12.2) (70), MGR7 (15q11.2-672 
q12) (71), MGR5 (19p13) (72), CACNA1A (19p13.2-13.1) (73), and MGR2 (Xq24-q28) (74). 673 
The genes used for mitral valve prolapse include AGTR1 (3q21-25) (75), MMVP2 (11p15.4) 674 
(76), MMVP3 (13q31.3-q32.1) (77), and MMVP1 (16p12.1-p11.2) (78). The genes used for 675 
myopia include MYP14 (1p36) (79), MYP12 (2q37.1) (80), MYP8 (3q26) (81), MYP11 (4q22-676 
q27) (82), MYP9 (4q12) (78), MYP16 (5p15.33-p15.2) (83), MYP4 (7q36) (84), MYP17 (7p15) 677 
(85), MYP10 (8p23) (81), MYP7 (11p13) (81), MYP3 (12q21-q23) (86), MYP5 (17q21-q22) 678 
(87), MYP1 (Xq28) (88), and MYP13 (Xq23-q25) (89). The genes used for seizures include 679 
SCN2A (2q23-24) (90) and CDKL5 (Xp22) (91). The genes used for scoliosis include CHD7 680 
(8q12.1-12.2) (92), IS4 (9q31.2-q34.2) (93), IS2 (17p11.2) (94), IS5 (17q25.3) (93), and AIS 681 
(19p13.3) (95). The gene used for tallness is GDF5 (20q11.2) (96). The gene used for Congenital 682 
Contractural Arachnodactyly (CCA, or Beals-Hecht syndrome), which can include symptoms 683 
such as long fingers, tall, thin, scoliosis, and mitral valve prolapse (97-99), is FBN2 (5q23-q31) 684 
(33). The gene used for Marfan Syndrome, which can include symptoms such as tall, thin, long 685 
fingers, scoliosis, and mitral valve prolapse (8, 99, 100), is FBN1 (15q21.1) (7). 686 
 687 
Figure 3. Traits present in parents and/or proband. Traits assayed here include the 10 traits 688 
we find most frequently associated with pectus excavatum. Traits shared between the proband 689 
and both parents are represented by yellow cells, between the proband and the mother by pink 690 
cells, between the proband and father, by light blue cells, in the proband only, by gray cells, in 691 
the mother only by dark red cells, in the father only by black cells, and between the mother and 692 




Table 1  695 
The ten clinical traits found to be most frequently associated with pectus excavatum (PE), ranked 696 












Table 2 709 

































 PE  Non-PE 
Trait % Rank  % Rank 
Thinness 47.41 1  3.55 7 
Braces 41.38 2  5.17 5 
Myopia 39.66 3  10.93 1 
Tallness 32.76 4  7.13 2 
Light Eyes 29.31 5  7.09 3 
Long Fingers 25.00 6  1.72 19 
Creativity 25.00 7  3.35 8 
Crowded Teeth 25.00 8  2.46 13 
Fair Skin 21.55 9  5.81 4 
Asthma 19.83 10  1.67 21 
Light Hair 14.66 13  3.10 9 
Arthritis 12.07 16  4.92 6 
Depression 8.63 22  3.00 10 















Table 3 720 
































Affected mothers  7  3  0.006  11.083  1.966‐
62.498 
